Soluble amyloid-β precursor peptide does not regulate GABAB receptor activity

Curation statements for this article:
  • Curated by eLife

    eLife logo

    eLife assessment

    This study refuted earlier work on the same subject. The two reviewers felt the manuscript was accurate, concise, and unbiased. The experimental evidence were thorough and supported the conclusions. The reviewers concurred the overall significance and quality of the experimental research were compelling and addressed previous work on this problem.

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

Amyloid-β precursor protein (APP) regulates neuronal activity through the release of secreted APP (sAPP) acting at cell surface receptors. APP and sAPP were reported to bind to the extracellular sushi domain 1 (SD1) of GABA B receptors (GBRs). A 17 amino acid peptide (APP17) derived from APP was sufficient for SD1 binding and shown to mimic the inhibitory effect of sAPP on neurotransmitter release and neuronal activity. The functional effects of APP17 and sAPP were similar to those of the GBR agonist baclofen and blocked by a GBR antagonist. These experiments led to the proposal that sAPP activates GBRs to exert its neuronal effects. However, whether APP17 and sAPP influence classical GBR signaling pathways in heterologous cells was not analyzed. Here, we confirm that APP17 binds to GBRs with nanomolar affinity. However, biochemical and electrophysiological experiments indicate that APP17 does not influence GBR activity in heterologous cells. Moreover, APP17 did not regulate synaptic GBR localization, GBR-activated K + currents, neurotransmitter release, or neuronal activity in vitro or in vivo. Our results show that APP17 is not a functional GBR ligand and indicate that sAPP exerts its neuronal effects through receptors other than GBRs.

Article activity feed

  1. Author Response

    Reviewer #1 (Public Review):

    The authors Rem et al., examine the mechanism of action of APP, a protein implicated in Alzheimer's disease pathology, on GABAB receptor function. It has been reported earlier that soluble APP (sAPP) binds to the Sushi domain 1 of the GABAB1a subunit. In the current manuscript, authors examine this issue in detail and report that sAPP or APP17 interacts with GABABR with nano Molar affinity. However, binding of APP to GABAB receptor does not influence any of the canonical effects such as receptor function, K+ channel currents, spontaneous release of glutamate, or EPSC in vivo. The experimental evidence provided to support the conclusions is thorough and statistically sound. The range of techniques used to address each of the aims has been carefully curated to draw meaningful conclusions.

    The authors use HEK293T heterologous cell line to confirm the affinity of APP17 for the receptor, ligand displacement, and receptor activation. They also use this method to study PKA activation downstream of the GPCR. They use slice electrophysiology to measure changes in glutamatergic transmission EPSC and then in vivo 2-photon microscopy to measure functional changes in vivo.

    The work is significant for the field of Alzheimer's and also GABAB receptor biology, as it has been assumed for sAPP acts via GABAB receptors to influence neurotransmission in the brain. The results presented here open up the question yet again, what is the physiological function of sAPP in the brain?

    The manuscript is clearly written and easy to follow. The main criticism would be that the manuscript fails to identify the mechanism downstream of APP17 interaction with GB1a SD1.

    Our results show that APP17 does not influence GABAB receptor signaling in heterologous expression systems, neuronal cultures and anesthetized mice. Thus, our data do not support the existence of a “mechanism downstream of APP17 interaction with GB1a SD1”. As discussed in our manuscript, full-length APP controls GABAB receptor trafficking and surface stability in axons (Dinamarca et al., 2019), thus already providing a biological function for binding of APP to GB1a.

  2. eLife assessment

    This study refuted earlier work on the same subject. The two reviewers felt the manuscript was accurate, concise, and unbiased. The experimental evidence were thorough and supported the conclusions. The reviewers concurred the overall significance and quality of the experimental research were compelling and addressed previous work on this problem.

  3. Reviewer #1 (Public Review):

    The authors Rem et al., examine the mechanism of action of APP, a protein implicated in Alzheimer's disease pathology, on GABAB receptor function. It has been reported earlier that soluble APP (sAPP) binds to the Sushi domain 1 of the GABAB1a subunit. In the current manuscript, authors examine this issue in detail and report that sAPP or APP17 interacts with GABABR with nano Molar affinity. However, binding of APP to GABAB receptor does not influence any of the canonical effects such as receptor function, K+ channel currents, spontaneous release of glutamate, or EPSC in vivo. The experimental evidence provided to support the conclusions is thorough and statistically sound. The range of techniques used to address each of the aims has been carefully curated to draw meaningful conclusions.

    The authors use HEK293T heterologous cell line to confirm the affinity of APP17 for the receptor, ligand displacement, and receptor activation. They also use this method to study PKA activation downstream of the GPCR. They use slice electrophysiology to measure changes in glutamatergic transmission EPSC and then in vivo 2-photon microscopy to measure functional changes in vivo.

    The work is significant for the field of Alzheimer's and also GABAB receptor biology, as it has been assumed for sAPP acts via GABAB receptors to influence neurotransmission in the brain. The results presented here open up the question yet again, what is the physiological function of sAPP in the brain?

    The manuscript is clearly written and easy to follow. The main criticism would be that the manuscript fails to identify the mechanism downstream of APP17 interaction with GB1a SD1.

  4. Reviewer #2 (Public Review):

    Amyloid-β precursor protein (APP) regulates synaptic activity in part through the release of secreted APP (sAPP) acting at cell-surface receptors. In 2019 two articles (Dinamarca et al, 2019; Rice et al, 2019) were published showing that sAPP binds with high affinity with GABAB receptors. These receptors regulate neuronal excitability and synaptic release. In the Rice et al. paper, it was concluded that sAPP plays a physiological role by regulating GABAB receptors by modulating synaptic transmission, consistent with the direct activation of these receptors by sAPP. This article has received major attention in the field of Alzheimer's disease and synaptic biology.

    The present work was designed to fully explore the functional consequences of sAPP binding to GABAB receptors, in particular, because it was unclear how a conformational change in SD1 - the region of GABAB receptors that binds sAPP - potentially induced by sAPP could increase GBR activity.
    The work does confirm that the peptide APP17 which derives from sAPP binds with nanomolar affinity with GABAB receptors. The authors use a diverse range of techniques, ranging from biophysical assays in recombinantly expressed receptors to electrophysiology and live imaging in cultured neurons, slices, and in vivo neuronal activity. In none of these assays, could the authors demonstrate any functional effect of sAPP mediated by an action on GABAB receptors.

    This work from a team that has exquisite knowledge of the different aspects of GABAB receptors represents an important and very convincing clarification for the field, and it would therefore be very useful if this information is rapidly available.